IL-27 Protein (His tag)

N° du produit ABIN7320591

Cette protéine Recombinant IL-27 est produite dans Human Cells.

Aperçu rapide pour IL-27 Protein (His tag) (ABIN7320591)

Antigène: IL-27 (IL27) (Interleukin 27 (IL27))

Type de proteíne: Recombinant

Origine: Souris

Source: Human Cells

Pureté: > 90 % as determined by SDS-PAGE

Détail du produit

Purification/Conjugué: Cette IL-27 protéine est marqué à la His tag.

Fonction: Recombinant Mouse Interleukin-27/IL-27 Protein (His Tag)

Séquence: Tyr19-Pro228&Phe29-Ser234

Attributs du produit: Recombinant Mouse Interleukin-27 subunit alpha and Interleukin-27 subunit beta is produced by our Mammalian expression system and the target gene encoding Tyr19-Pro228&Phe29-Ser234 is expressed with a 6His tag at the C-terminus.

niveau d'endotoxine: < 1.0 EU per μg as determined by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from a 0.2 μm filtered solution of PBS,2 mM EDTA,5 % Mannitol, pH 7.4.

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Détail du antigène

Antigène: IL-27 (IL27) (Interleukin 27 (IL27))

Autre désignation: Interleukin-27/IL-27

Sujet:

Background: IL-27 is a heterodimeric cytokine which belongs to the IL-6/IL-12 family of long type I cytokines. It is expressed on monocytes, endothelial cells and dendritic cells. IL-27 is an early product of activated antigen-presenting cells and drives rapid clonal expansion of naive CD4(+) T cells and plays a role in the early regulation of Th1 cells initiation which drives efficient adaptive immune response. IL-27 potentiates the early phase of TH1 response and suppresses TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. IL-27 has an antiproliferative activity on melanomas through WSX-1/STAT1 signaling. Thus, IL-27 protein may be an attractive candidate as an antitumor agent applicable to cancer immunotherapy. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. IL-27 has also an effect on cytokine production. It suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9.

Synonym: Interleukin-27 subunit alpha,IL-27 subunit alpha,IL-27-A,IL27-A,p28,Il27,Il27a,Interleukin-27 subunit beta,Ebi3,IL-27 subunit beta,IL-27B,Epstein-Barr virus-induced gene 3 protein homolog,Ebi3,Il27b

Poids moléculaire: 49 kDa